Question 1

What is Setmelanotide?

Accepted Answer

Setmelanotide is a Other.

Question 2

How often does Setmelanotide appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Setmelanotide first tracked by Ergen?

Accepted Answer

First tracked on May 01, 2026.

Question 4

When was Setmelanotide last mentioned in news?

Accepted Answer

Last active on May 04, 2026.

Question 5

What is Setmelanotide's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Setmelanotide in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Setmelanotide?

Accepted Answer

IMCIVREE EU Approval, Positive Data (May 01, 2026, 6 articles).

Question 8

How did the "IMCIVREE EU Approval, Positive Data" event impact Setmelanotide?

Accepted Answer

Setmelanotide (setmelanotide) received expanded marketing authorization from the International — European Commission for acquired hypothalamic obesity, and its long-term efficacy data was presented, indicating significant potential for Rhythm Pharmaceuticals.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.